ChenGuang Biotech Group Future Growth

Future criteria checks 3/6

ChenGuang Biotech Group is forecast to grow earnings and revenue by 25.4% and 13.3% per annum respectively. EPS is expected to grow by 25.4% per annum. Return on equity is forecast to be 14.6% in 3 years.

Key information

25.4%

Earnings growth rate

25.4%

EPS growth rate

Food earnings growth	32.5%
Revenue growth rate	13.3%
Future return on equity	14.6%
Analyst coverage	Low
Last updated	26 Apr 2024

Recent future growth updates

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

Recent updates

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21

Earnings and Revenue Growth Forecasts

SZSE:300138 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	9,478	699	N/A	N/A	2
12/31/2025	8,843	659	N/A	N/A	5
12/31/2024	7,237	393	N/A	N/A	3
3/31/2024	6,786	389	N/A	N/A	N/A
12/31/2023	6,872	480	-778	-588	N/A
9/30/2023	6,770	489	N/A	N/A	N/A
6/30/2023	6,737	492	286	453	N/A
3/31/2023	6,529	462	489	627	N/A
12/31/2022	6,296	434	559	735	N/A
9/30/2022	6,465	429	291	478	N/A
6/30/2022	6,002	403	36	244	N/A
3/31/2022	5,446	380	-587	-329	N/A
12/31/2021	4,874	352	-217	64	N/A
9/30/2021	4,410	322	59	407	N/A
6/30/2021	4,186	304	46	455	N/A
3/31/2021	4,188	285	225	715	N/A
1/1/2021	3,913	268	93	529	N/A
9/30/2020	3,667	252	272	667	N/A
6/30/2020	3,481	235	36	405	N/A
3/31/2020	3,288	206	-170	88	N/A
12/31/2019	3,265	194	-290	-24	N/A
9/30/2019	3,226	165	70	292	N/A
6/30/2019	3,378	162	29	207	N/A
3/31/2019	3,139	146	-196	-37	N/A
1/1/2019	3,063	145	-196	-56	N/A
9/30/2018	2,799	155	-536	-381	N/A
6/30/2018	2,779	159	-416	-283	N/A
3/31/2018	2,807	155	-306	-176	N/A
12/31/2017	2,772	143	N/A	-146	N/A
9/30/2017	2,780	129	N/A	-55	N/A
6/30/2017	2,384	120	N/A	-292	N/A
3/31/2017	2,259	111	N/A	-354	N/A
12/31/2016	2,141	92	N/A	-322	N/A
9/30/2016	1,824	99	N/A	125	N/A
6/30/2016	1,636	79	N/A	156	N/A
3/31/2016	1,474	80	N/A	44	N/A
12/31/2015	1,268	69	N/A	-65	N/A
9/30/2015	1,246	59	N/A	54	N/A
6/30/2015	1,287	57	N/A	178	N/A
3/31/2015	1,205	24	N/A	209	N/A
12/31/2014	1,207	22	N/A	273	N/A
9/30/2014	1,238	21	N/A	266	N/A
6/30/2014	1,174	4	N/A	117	N/A
3/31/2014	1,131	3	N/A	38	N/A
12/31/2013	1,186	10	N/A	-36	N/A
9/30/2013	1,107	21	N/A	53	N/A
6/30/2013	1,072	32	N/A	-53	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 300138's forecast earnings growth (25.4% per year) is above the savings rate (2.9%).

Earnings vs Market: 300138's earnings (25.4% per year) are forecast to grow faster than the CN market (24.1% per year).

High Growth Earnings: 300138's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 300138's revenue (13.3% per year) is forecast to grow slower than the CN market (14.7% per year).

High Growth Revenue: 300138's revenue (13.3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 300138's Return on Equity is forecast to be low in 3 years time (14.6%).

ChenGuang Biotech Group Future Growth

Future criteria checks 3/6

Key information

Recent future growth updates

Price target decreased by 7.3% to CN¥17.31

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Price target decreased by 8.0% to CN¥20.43

Consensus revenue estimates increase by 11%

Price target increased to CN¥20.80

Recent updates

Price target decreased by 7.3% to CN¥17.31

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Consensus EPS estimates fall by 15%, revenue upgraded

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

ChenGuang Biotech Group Co., Ltd., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 16%

ChenGuang Biotech Group Co., Ltd. to Report Q1, 2024 Results on Apr 25, 2024

Full year 2023 earnings released: EPS: CN¥0.91 (vs CN¥0.81 in FY 2022)

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 18, 2024

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) commences an Equity Buyback Plan for CNY 100 million worth of its shares, under the authorization approved on November 17, 2023.

Price target decreased by 8.0% to CN¥20.43

Third quarter 2023 earnings released: EPS: CN¥0.19 (vs CN¥0.18 in 3Q 2022)

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2023 Results on Oct 24, 2023

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Chenguang Biotech Group Co., Ltd. Announces Management Appointment

ChenGuang Biotech Group Co., Ltd. Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2022, Payable on 17 May 2023

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.20 in 1Q 2022)

Full year 2022 earnings released: EPS: CN¥0.82 (vs CN¥0.67 in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: EPS: CN¥0.18 (vs CN¥0.12 in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Chenguang Biotech Group Co., Ltd. Announces 2021 Final Cash Dividend Proposal on A Shares, Payable on 1 June 2022

Consensus revenue estimates increase by 11%

Insufficient new directors

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chenguang Biotech Group Co., Ltd. Approves Cash Dividend

Full year 2021 earnings: EPS and revenues exceed analyst expectations

ChenGuang Biotech Group Co., Ltd. Announces Final Dividend For the Year 2021

Price target increased to CN¥20.80

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.11 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.15 (vs CN¥0.12 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.54 (vs CN¥0.38 in FY 2019)

Revenue and earnings beat expectations

ChenGuang Biotech Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 23, 2021

New 90-day low: CN¥15.29

Investor sentiment deteriorated over the past week

New 90-day high: CN¥19.53

Market bids up stock over the past week

New 90-day high: CN¥18.18

Third quarter earnings released

ChenGuang Biotech Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) agreed to acquire an additional 24.83% stake in Xinjiang Tianjiao Hongan Agricultural Technology Co., Ltd. from Xinjiang Longping Gaoke Hong'an Seed Industry Co., Ltd. for CNY 20 million.

Earnings released

ChenGuang Biotech Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥16.99

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) cancelled the acquisition of 10% stake in Tengchong Kang’enpu Biological Materials Co., Ltd. from Zhu Jingbo, Chen Xin and Zhang Jiaqi.

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies